INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) Profiling Identifies Ambulatory Patients at High Risk on Medical Therapy after Hospitalizations for Heart Failure

Circulation: Heart Failure

Volumn 9, Issue 11, 2016, Pages

  Stewart, Garrick C ^a   Kittleson, Michelle M ^b   Patel, Parag C ^c   Cowger, Jennifer A ^d   Patel, Chetan B ^e   Mountis, Maria M ^f   Johnson, Frances L ^g   Guglin, Maya E ^h   Rame, J Eduardo ⁱ   Teuteberg, Jeffrey J ^j   Stevenson, Lynne W ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF IOWA   (United States)

^h UNIVERSITY OF SOUTH FLORIDA   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Heart failure; hospitalization; outcome measures; quality of life; registries

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; NITRIC ACID DERIVATIVE; VASODILATOR AGENT;

ADULT; AGED; CARDIAC RESYNCHRONIZATION THERAPY; DISEASE EXACERBATION; FEMALE; HEART ASSIST DEVICE; HEART FAILURE; HEART STROKE VOLUME; HOSPITALIZATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MALE; MIDDLE AGED; MORTALITY; OUTPATIENT; PATHOPHYSIOLOGY; PROGNOSIS; PROSPECTIVE STUDY; QUALITY OF LIFE; REGISTER; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIAC RESYNCHRONIZATION THERAPY; DEFIBRILLATORS, IMPLANTABLE; DISEASE PROGRESSION; FEMALE; HEART FAILURE; HEART-ASSIST DEVICES; HOSPITALIZATION; HUMANS; HYDRALAZINE; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NITRATES; OUTPATIENTS; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; REGISTRIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; STROKE VOLUME; VASODILATOR AGENTS;

EID: 84995810300     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.116.003032     Document Type: Article

References (24)

1. Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Miller MA, Timothy Baldwin J, Young JB. Sixth INTERMACS annual report: a 10,000-patient database. J Heart Lung Transplant. 2014;33:555-564.
2. UAB School of Medicine. Interagency Registry of Mechanically Assisted Circulatory Support. www.intermacs.org. Accessed October 2015.
3. Stewart GC, Stevenson LW. Keeping left ventricular assist device acceleration on track. Circulation. 2011;123:1559-1568; discussion 1568. doi: 10.1161/CIRCULATIONAHA.110.982512.
4. US Food and Drug Administration. Serious Adverse Events with Implantable Left Ventricular Assist Devices (LVADs): FDA Safety Communication. http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm 457327.htm. Accessed October 26, 2016.
5. Mehra MR, Stewart GC, Uber PA. The vexing problem of thrombosis in long-term mechanical circulatory support. J Heart Lung Transplant. 2014;33:1-11. doi: 10.1016/j.healun.2013.12.002.
6. Stevenson LW, Pagani FD, Young JB, Jessup M, Miller L, Kormos RL, Naftel DC, Ulisney K, Desvigne-Nickens P, Kirklin JK. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant. 2009;28:535-541. doi: 10.1016/j.healun.2009.02.015.
7. Levy WC, Mozaffarian D, Linker DT, Farrar DJ, Miller LW; REMATCH Investigators. Can the Seattle Heart Failure Model be used to riskstratify heart failure patients for potential left ventricular assist device therapy? J Heart Lung Transplant. 2009;28:231-236. doi: 10.1016/j. healun.2008.12.015.
8. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006;113:1424-1433. doi: 10.1161/CIRCULATIONAHA.105.584102.
9. Cowger J, Sundareswaran K, Rogers JG, Park SJ, Pagani FD, Bhat G, Jaski B, Farrar DJ, Slaughter MS. Predicting survival in patients receiving continuous flow left ventricular assist devices: the HeartMate II risk score. J Am Coll Cardiol. 2013;61:313-321. doi: 10.1016/j. jacc.2012.09.055.
10. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337-343.
11. Flynn KE, Lin L, Ellis SJ, Russell SD, Spertus JA, Whellan DJ, Pinã IL, Fine LJ, Schulman KA, Weinfurt KP; HF-ACTION Investigators. Outcomes, health policy, and managed care: relationships between patient-reported outcome measures and clinical measures in outpatients with heart failure. Am Heart J. 2009;158(4 suppl):S64-S71. doi: 10.1016/j.ahj.2009.07.010.
12. Grady KL, Naftel D, Stevenson L, Dew MA, Weidner G, Pagani FD, Kirklin JK, Myers S, Baldwin T, Young J. Overall quality of life improves to similar levels after mechanical circulatory support regardless of severity of heart failure before implantation. J Heart Lung Transplant. 2014;33:412-421. doi: 10.1016/j.healun.2013.10.017.
13. McGiffin DC, Naftel DC, Kirklin JK, Morrow WR, Towbin J, Shaddy R, Alejos J, Rossi A. Predicting outcome after listing for heart transplantation in children: comparison of Kaplan-Meier and parametric competing risk analysis. Pediatric Heart Transplant Study Group. J Heart Lung Transplant. 1997;16:713-722.
14. Gorodeski EZ, Chu EC, Chow CH, Levy WC, Hsich E, Starling RC. Application of the Seattle Heart Failure Model in ambulatory patients presented to an advanced heart failure therapeutics committee. Circ Heart Fail. 2010;3:706-714. doi: 10.1161/CIRCHEARTFAILURE.110.944280.
15. Center for Medicare and Medicaid Services. National Coverage Determination (NCD) for Artificial Hearts and Related Devices (20.9). https://www.cms.gov/medicare-coverage-database/(S(fifmbk55z kfkik552iwqmivv))/details/ncd-details.aspx?NCDId=246&ncdver=5& NCAId=243&ver=5&ExpandComments=n&NcaName=Ventricular+As sist+Devices+as+Destination+Therapy+(2nd+Recon)&bc=BEAAAAA AEAgA&. Accessed October 26, 2016.
16. Kirklin JK, Naftel DC, Kormos RL, Pagani FD, Myers SL, Stevenson LW, Acker MA, Goldstein DL, Silvestry SC, Milano CA, Baldwin JT, Timothy Baldwin J, Pinney S, Eduardo Rame J, Miller MA. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. J Heart Lung Transplant. 2014;33:12-22. doi: 10.1016/j. healun.2013.11.001.
17. Starling RC, Moazami N, Silvestry SC, Ewald G, Rogers JG, Milano CA, Rame JE, Acker MA, Blackstone EH, Ehrlinger J, Thuita L, Mountis MM, Soltesz EG, Lytle BW, Smedira NG. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med. 2014;370:33-40. doi: 10.1056/NEJMoa1313385.
18. Estep JD, Starling RC, Horstmanshof DA, Milano CA, Selzman CH, Shah KB, Loebe M, Moazami N, Long JW, Stehlik J, Kasirajan V, Haas DC, O'Connell JB, Boyle AJ, Farrar DJ, Rogers JG; ROADMAP Study Investigators. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: results from the ROADMAP Study. J Am Coll Cardiol. 2015;66:1747-1761. doi: 10.1016/j.jacc.2015.07.075.
19. Stewart GC, Kittleson MM, Cowger JA, Johnson FL, Patel CB, Mountis MM, Patel PC, Rame JE, Testani J, Guglin ME, Teuteberg JJ, Stevenson LW. Who wants a left ventricular assist device for ambulatory heart failure? Early insights from the MEDAMACS screening pilot. J Heart Lung Transplant. 2015;34:1630-1633.
20. Baldwin JT, Mann DL. NHLBI's program for VAD therapy for moderately advanced heart failure: the REVIVE-IT pilot trial. J Card Fail. 2010;16:855-858. doi: 10.1016/j.cardfail.2010.06.414.
21. Stewart GC, Stevenson LW. INTERMACS and MedaMACS: how will they guide future therapy? Curr Cardiol Rep. 2013;15:394. doi: 10.1007/s11886-013-0394-y.
22. Stewart GC, Brooks K, Pratibhu PP, Tsang SW, Semigran MJ, Smith CM, Saniuk C, Camuso JM, Fang JC, Mudge GH, Couper GS, Baughman KL, Stevenson LW. Thresholds of physical activity and life expectancy for patients considering destination ventricular assist devices. J Heart Lung Transplant. 2009;28:863-869. doi: 10.1016/j. healun.2009.05.016.
23. Allen LA, Stevenson LW, Grady KL, Goldstein NE, Matlock DD, Arnold RM, Cook NR, Felker GM, Francis GS, Hauptman PJ, Havranek EP, Krumholz HM, Mancini D, Riegel B, Spertus JA; American Heart Association; Council on Quality of Care and Outcomes Research; Council on Cardiovascular Nursing; Council on Clinical Cardiology; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Surgery and Anesthesia. Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation. 2012;125:1928-1952. doi: 10.1161/CIR.0b013e31824f2173.
24. Bruce CR, Blumenthal-Barby JS, Meyers D. Benefits and challenges of early introduction of left ventricular assist device placement: a patient-centered perspective. J Am Coll Cardiol. 2015;66:1762-1765. doi: 10.1016/j.jacc.2015.08.852.